For research use only. Not for therapeutic Use.
DL-AP3 is a competitive mGluR1 and mGluR5 antagonist. DL-AP3 is also an inhibitor of phosphoserine phosphatase. DL-AP3 has neuroprotective effect[1][2][3].
DL-AP3 (10 µM, 6 h) alleviates oxygen-glucose deprivation (OGD)-induced injury (cell viability) in primary neurons[1].
DL-AP3 (10 µM, 6 h) recovers the decreased levels of p-Akt1 and the increase of cytochrome C induced by OGD in primary neurons[1].
DL-AP3 (1-100 µM) inhibits activity of rat brain phosphoserine phosphatase, with an IC50 of 187 µM and Ki of 77 µM[2].
DL-AP3 (10 μM, 10 min) together with SKF81297 (5 μM) induces a significant Long-term potentiation (LTP) in the slices of Fmr1 KO mice[3].
DL-AP3 (4 mg/kg, i.p., for 5 weeks) with SKF81297 (1 mg/kg, i.p.) reduces the hyperactivity phenotype in Fmr1 KO mice[3].
DL-AP3 (4.0-12.0 mg/animal, i.c.v. infusion, 100 μL) blocks development of visceral pain symptoms and neuroendocrinological changes in the blood plasma of sheep[4].
| Catalog Number | R045675 |
| CAS Number | 5652-28-8 |
| Synonyms | 2-amino-3-phosphonopropanoic acid |
| Molecular Formula | C3H8NO5P |
| Purity | ≥95% |
| InChI | InChI=1S/C3H8NO5P/c4-2(3(5)6)1-10(7,8)9/h2H,1,4H2,(H,5,6)(H2,7,8,9) |
| InChIKey | LBTABPSJONFLPO-UHFFFAOYSA-N |
| SMILES | C(C(C(=O)O)N)P(=O)(O)O |
| Reference | [1]. Cui D, et al. DL-2-amino-3-phosphonopropionic acid protects primary neurons from oxygen-glucose deprivation induced injury. Bosn J Basic Med Sci. 2017 Feb 21;17(1):12-16. [2]. Hawkinson JE, et al. The metabotropic glutamate receptor antagonist L-2-amino-3-phosphonopropionic acid inhibits phosphoserine phosphatase. Eur J Pharmacol. 1996 Jun 27;307(2):219-25. [3]. Xu ZH, et al. Group I mGluR antagonist rescues the deficit of D1-induced LTP in a mouse model of fragile X syndrome. Mol Neurodegener. 2012 May 28;7:24. [4]. B.F. Kania, et al. Supraspinal basis of analgesic and clinical effects of the metabotropic glutamate mGluR1 antagonist during colonic distension in sheep. Small Ruminant Research. 2014. 117 (1). |
